Articles tagged with Cancer Medication
A study published in the World Journal of Gastroenterology found that gemcitabine-oxaliplatin combined with Huachansu improved the quality of life in patients with advanced gallbladder carcinoma, with a disease control rate of 65.2% and median overall survival of 10.5 months.
Researchers at Stanford University School of Medicine have discovered a novel 'double agent' role for glycogen synthase kinase 3 (GSK3) in regulating cell growth. Inhibiting GSK3 combats leukemias caused by mutated MLL genes, which account for five to 10 percent of child and adult leukemias.
A phase III clinical trial led by UC Irvine's Dr. Bradley Monk found trabectedin to be effective in stopping ovarian cancer cell growth, with a median progression-free time of 9.2 months for those treated with the combination therapy. The treatment has hope for improved treatment of this deadly disease.
A new combination therapy of trabectedin and pegylated liposomal doxorubicin shows clinical benefit for women with relapsed ovarian cancer. The treatment offers an alternative to traditional platinum-based regimens, providing a fresh option for those whose cancer recurs after first-line treatment.
A study by the European Society for Medical Oncology found substantial variation in the uptake of newer cancer drugs across EU countries. The cost of these drugs is a major barrier to access, and their complexity can make them harder to understand and use effectively.
A phase II trial of the investigational drug pazopanib has shown promising results in treating ovarian cancer. The study found that 31% of patients experienced a significant decrease in CA-125 levels, with a median duration of response of 113 days.
Researchers develop nanoparticles that deliver siRNA to cancer cells, reducing tumor growth and size by up to 70%. Targeting multiple genes simultaneously leads to synergistic effects, offering a promising personalized medicine approach.
A team of Fox Chase researchers has identified a single genetic mutation as a key factor in the development of colorectal cancer. By studying individuals with a inherited 'one-hit' gene mutation, they discovered molecular changes that signal cancer presence and potential targets for preventive drugs.
The American College of Physicians released a new clinical practice guideline recommending drug treatment for men and women with osteoporosis or low bone density. In addition, massage therapy may have an immediate positive effect on pain and mood for advanced cancer patients, according to a study from the National Institutes of Health.
Scientists at Dana-Farber Cancer Institute have identified a previously unsuspected gene, CDK8, as a cancer-causing gene in many colon cancers. The study suggests that blocking CDK8 may be useful against tumors driven by overactive beta-catenin.
Regular NSAID use can reduce serum PSA levels, potentially altering prostate cancer detection in individuals taking these medications. Chronic inflammation linked to prostate cancer may be masked by NSAIDs, which inhibit COX enzymes.
Researchers found that anti-angiogenic drugs block chemotherapy-induced blood vessel formation, thereby hindering tumor regrowth. This mechanism may explain why some chemotherapy combinations enhance treatment efficacy.
Common painkillers such as aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker used to gauge prostate cancer risk. However, the study does not prove a direct link between the medications and reduced risk of prostate cancer.
A new treatment strategy involving sorafenib could 're-sensitize' tumors, enabling anti-hormonal drugs like aromatase inhibitors to be effective again. Preliminary analysis shows a clinical benefit response in 26 percent of patients taking both sorafenib and anastrozole.
Researchers discovered that injections of N-acetyl cysteine (NAC) can prevent memory loss induced by breast cancer chemotherapy drugs. The study, published in the Springer journal Metabolic Brain Disease, suggests a potential remedy for chemobrain symptoms, which affect up to 40% of cancer patients undergoing chemotherapy.
Yale researchers identified a molecular process in normal tissues that causes RNA molecules to be clipped and stitched together, potentially complicating cancer diagnosis and predicting anti-cancer drug side effects. The discovery suggests that cancers may mimic normal cellular processes, leading to unpredictable toxicities.
Scientists have discovered that phosphatidic acid, a phospholipid component of cellular membranes, may be a promising novel anti-cancer drug target. Researchers found that siramesine, a previously failed anxiety medication, effectively inhibits the growth of cancer cells and tumors in mice.
Michelle Krogsgaard, a NYU Cancer Institute pathologist, has been awarded the NIH EUREKA grant to explore novel techniques in T-cell signaling. Her research aims to enhance the immune response in patients with HIV or cancer and diminish T-cell activation in autoimmune disease.
Researchers at TGen and Washington University School of Medicine have discovered a new approach to treating endometrial cancer using a commercially available inhibitor drug. The study found that the drug can stop tumor growth and kill cancer cells, even in cases where the tumors contain a commonly occurring mutant gene.
Researchers at The Wistar Institute have deciphered the structure of telomerase, an enzyme playing a major role in nearly all human cancers. This achievement paves the way for new cancer treatments and anti-aging therapies by understanding how to deactivate telomerase.
Researchers found that a specific PMS2 protein variant can render cancer cells resistant to cisplatin, a common chemotherapy drug. The study suggests personalized therapies may be developed for patients carrying this variant.
Scientists at the University of York have discovered a new role for Natural Killer cells, which can make diseases worse in certain cases. The research suggests that these cells produce chemicals that inhibit immune responses, leading to potential breakthroughs in treating chronic infections and cancer.
A decade of research into Jasmonate, a synthetic compound derived from the jasmine flower, has led to the development of an anti-cancer drug. Early first-in-man studies have proven successful, with the compound showing responsiveness to both blood cancers and solid tumors.
Researchers at Beth Israel Deaconess Medical Center discovered that PTEN tumor suppression is maintained through a nuclear localization pathway. The study found that the loss of PML and HAUSP can force PTEN out of the nucleus, preventing its ability to act as a tumor suppressor.
Researchers have engineered the first drug-delivery particles capable of passing through human mucus, which could treat a range of diseases. The new system uses a polymer coating to allow drugs to penetrate mucus layers in minutes.
Researchers at Stanford University have developed a method to get around one of the most common forms of resistance, thereby opening up some resistant diseases to the reinvigorated fury of medications. The method uses an arginine-rich transporter to deliver potent medication inside a resistant cell.
Researchers at Stanford University have developed a new method using single-walled carbon nanotubes as delivery vehicles for cancer chemotherapy drugs. They found that the nanotubes can deliver up to 10 times more medication into tumor cells than traditional formulations, reducing side effects and improving treatment outcomes.
Researchers use ruthenium as a catalyst to increase oxidant levels in infected cells, ultimately destroying cancerous cells. The study offers a promising alternative to traditional cancer treatments, which often adapt quickly to targeted drugs.
University of Florida researchers have discovered a marine compound called largazole that inhibits cancer cell growth in laboratory tests. The compound is derived from cyanobacteria and targets histone deacetylase enzymes, which are associated with several cancers.
Researchers at NYU Cancer Institute have identified mebendazole as a potential treatment for metastatic melanoma, exploiting its ability to target cancer-causing proteins. By inactivating the protein Bcl-2, mebendazole induces programmed cell death in malignant melanoma cells.
University of Manchester researchers have taken a systematic approach to studying anti-mitotic drugs, revealing a profound variation in cell behavior among different tumors. The study aims to improve the effectiveness of these drugs while reducing side effects such as nerve damage.
A UNC study reveals that nanoparticles designed with a specific shape, size, and surface chemistry are taken up by cells differently depending on these attributes. This finding could lead to more effective treatment methods for various diseases, including cancer and diabetes.
New studies presented at the XVII International AIDS Conference confirm a clear threshold response for DNA damage caused by ethyl methanesulfonate (EMS) in Viracept. The research finds that patients exposed to elevated EMS levels are not at increased risk of cancer, despite levels below this threshold.
Researchers found that each type of cancer has distinct gene mutations that provide a 'selective advantage', driving tumor formation through evolution. This discovery improves our understanding of how evolution shapes life and lays the groundwork for new cancer treatments.
A study published in The American Journal of Pathology suggests that fibrocytes, cells involved in wound healing, can form premetastatic niches that facilitate cancer spread. Researchers found that injecting these cells into mice nearly doubled the rate of metastasis, a finding that could lead to new treatments.
The presence of an impurity called ethyl methanesulfonate (EMS) in Roche's Viracept HIV medication did not increase patients' risk of developing cancer, according to new research confirmed by the European Committee for Human Medicinal Products (CHMP).
Scientists at NYU Langone Medical Center have identified a new cellular pathway that responds to DNA damage and is linked to the development of cancer. The pathway involves a process that targets proteins for disposal, which could potentially be used to sensitize cancer cells to treatment.
Researchers at Mount Sinai School of Medicine found that sorafenib increases overall survival by 44% compared to placebo in advanced liver cancer patients. The study also showed a significant delay in cancer progression.
Researchers at Case Western Reserve University have developed a technique that can deliver cancer-fighting drugs to diseased areas within hours, reducing the current delivery time from two days. The system uses gold nanoparticle vectors to deliver photodynamic therapy (PDT) drugs through the bloodstream.
Researchers at Cold Spring Harbor Laboratory have identified Top2A and Top1 enzymes as significant contributors to chemotherapy drug resistance. The team developed a novel screening technique to investigate the genetic basis of cancer therapy response, which could be applied widely to explore genetic mechanisms underlying drug resistance.
A team of researchers at Ohio State University received a $10.9M NCI grant to investigate how retroviruses cause cancer in white blood cells. The five-year project aims to define critical biological events that control lymphocyte alteration and identify therapeutic targets.
A worldwide study found significant differences in cancer survival rates between rich and poor countries, as well as between black and white men and women in the US. Cancer survival varies widely across regions, with some countries having much higher or lower survival rates than others.
Researchers have discovered that a natural compound from magnolia cones can block a previously 'undruggable' pathway for cancer growth. This finding could lead to the development of new treatments by making tumors more sensitive to traditional chemotherapy drugs.
Researchers found that an HDAC inhibitor, SAHA, significantly diminishes the destructive effects of dendritic cells in graft-versus-host disease, offering a novel treatment option. The study suggests a potential new approach to treating the major complication of bone marrow transplants and autoimmune diseases.
Scientists have discovered a chemical mechanism by which argyrin destroys tumours and prevents protein breakdown, leading to reduced tumour growth and no side effects. Researchers are now working to optimize the molecule for clinical testing in the near future.
A new ovarian stimulation technique allows women with cancer to collect eggs for freezing during the luteal phase, reducing wait time before treatment. The technique has shown promising results in triggering ovulation and collecting mature eggs within two weeks.
Scientists identified a new antitumor drug, argyrin A, derived from the myxobacterium Archangium gephyra, which stabilizes the tumor suppressor protein p27kip1. The peptide induces apoptosis in cancer cells and prevents new tumor blood vessels from forming.
Researchers at UC San Diego develop a nanoscale drug delivery system targeting integrin ανβ3 protein on tumor blood vessels, reducing collateral damage. The approach shows promise in treating metastatic disease with lower chemotherapy doses.
Scientists have identified marine species that produce compounds interfering with NF-kB, a protein linked to cancer and other diseases. These compounds may allow normal cell death in cancerous cells, while also improving drug delivery to tumors and other targeted areas.
Researchers at UCLA have solved the structure of sodium glucose co-transporters (SGLTs), which pump glucose into cells. This breakthrough may lead to improved treatments for diabetes and obesity.
University of Manchester researchers have received £1.6 million in funding to study a group of genes identified as playing a key role in leukaemia. The grant will help analyze the common mechanisms of action for patient benefit, potentially leading to the development of targeted therapies.
A clinical trial found that motesanib diphosphate, a VEGF inhibitor, slowed disease progression in some patients with metastatic thyroid cancer. The study also identified a genetic mutation associated with better response rates, offering potential for personalized therapy.
Researchers at Stanford University School of Medicine found that lowering levels of signaling molecule Myc to a specific threshold reverses cancer cell growth and returns tumor cells to their normal state. This breakthrough could lead to more effective cancer chemotherapy with fewer side effects for healthy cells.
Lodamin, a novel oral angiogenesis inhibitor, has shown promising anticancer results in mice, demonstrating its potential as a preventive therapy for patients at high risk of cancer. The drug selectively accumulates in tumor tissue, blocks angiogenesis, and inhibits primary tumor growth without apparent side effects.
Researchers at McGill University have discovered a compound called silvestrol that can re-sensitize tumors to chemotherapy, making them susceptible to anticancer drugs. Silvestrol, derived from Malaysian folk medicine, has been shown to effectively reduce resistance to chemotherapy agents used to treat cancer.
A study published in Nature Medicine reveals that combining tPA with the leukemia drug imatinib reduces the risk of brain bleeding in mice, even when given late after stroke onset. This finding has great promise for increasing the effectiveness of tPA treatment in stroke patients.
A study found that chemicals in cigarette smoke activate nerves in guinea pig airways, causing damage. Leptin levels also play a role in weight loss, with low levels helping protect against weight regain.
A University of Michigan study reveals how the CHFR gene affects breast cell division, leading to genomic instability and cancer. The loss of CHFR disrupts chromosome segregation, creating conditions for cancer cells to grow and thrive.
Withdrawing calcineurin inhibitors after kidney transplantation can prolong survival, improve kidney function, and save money compared to lifelong medication use. The study found that treatment with sirolimus plus steroids may be more efficacious and less costly than regimens using calcineurin inhibitors.
A new class of compounds, cyclopenta[b]benzofuran flavaglines, has been found to inhibit translation initiation and reverse cancer cell resistance to anticancer agents. This approach targets the eIF4A protein, which plays a central role in translation initiation.